BeiGene, Ltd. (NASDAQ:BGNE – Get Free Report) has been given an average recommendation of “Moderate Buy” by the seven research firms that are covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $241.21.
Several equities analysts have recently weighed in on BGNE shares. Bank of America reduced their price target on BeiGene from $180.00 to $152.50 and set a “neutral” rating for the company in a research report on Tuesday, July 9th. JMP Securities started coverage on BeiGene in a research report on Wednesday, September 18th. They issued a “market outperform” rating and a $288.00 price target for the company. Citigroup lifted their price target on BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Finally, JPMorgan Chase & Co. lifted their price target on BeiGene from $194.00 to $200.00 and gave the company an “overweight” rating in a research report on Tuesday, August 20th.
Check Out Our Latest Research Report on BeiGene
Insider Buying and Selling
Hedge Funds Weigh In On BeiGene
A number of hedge funds and other institutional investors have recently modified their holdings of BGNE. Capital International Investors boosted its holdings in shares of BeiGene by 11.5% in the 1st quarter. Capital International Investors now owns 7,064,428 shares of the company’s stock worth $1,104,806,000 after purchasing an additional 727,556 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in shares of BeiGene in the 2nd quarter worth about $54,412,000. M&G Plc purchased a new position in shares of BeiGene in the 1st quarter worth about $29,649,000. Goldman Sachs Group Inc. lifted its stake in shares of BeiGene by 175.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 214,339 shares of the company’s stock valued at $38,658,000 after acquiring an additional 136,458 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of BeiGene by 6.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,026,094 shares of the company’s stock valued at $316,862,000 after acquiring an additional 117,905 shares during the last quarter. 48.55% of the stock is currently owned by hedge funds and other institutional investors.
BeiGene Stock Performance
Shares of BGNE opened at $222.60 on Friday. The firm has a market cap of $21.57 billion, a PE ratio of -29.41 and a beta of 0.62. The stock’s fifty day moving average price is $205.15 and its two-hundred day moving average price is $172.25. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.98 and a quick ratio of 1.75. BeiGene has a 1 year low of $126.97 and a 1 year high of $248.16.
BeiGene (NASDAQ:BGNE – Get Free Report) last issued its earnings results on Wednesday, August 7th. The company reported ($1.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.27) by $1.12. The firm had revenue of $929.20 million for the quarter, compared to analyst estimates of $810.34 million. BeiGene had a negative return on equity of 14.93% and a negative net margin of 16.91%. The business’s revenue was up 56.1% on a year-over-year basis. During the same period in the previous year, the company posted ($3.64) earnings per share. On average, equities research analysts forecast that BeiGene will post -5.07 EPS for the current year.
About BeiGene
BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.
Read More
- Five stocks we like better than BeiGene
- What is a Bond Market Holiday? How to Invest and Trade
- Goldman Sachs Earnings Reveal Market Moves Investors Can’t Ignore
- What Are the U.K. Market Holidays? How to Invest and Trade
- AMD Gains Momentum With AI: Can It Beat Expectations?
- How is Compound Interest Calculated?
- Lithium Grab: 2 Lithium Stocks That Could Be Takeover Targets
Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.